Literature DB >> 14669077

Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients.

Hideyuki Ishida1, Nobuo Murata, Yoichi Hayashi, Masakazu Tada, Daijo Hashimoto.   

Abstract

PURPOSE: Expression of tissue inhibitor of metalloproteinases (TIMP)-1 in colorectal cancer tissue is known to be related to disease progression; however, the clinical significance of measuring the blood level of TIMP-1, which we evaluate herein, has not yet been clarified.
METHODS: The serum level of TIMP-1 was measured by a one-step enzyme immunoassay in 123 patients who underwent resection of primary colorectal cancer.
RESULTS: An elevated level of serum TIMP-1 was associated with advanced Dukes' stage ( P = 0.03), greater diameter of the primary tumor ( P = 0.03), more lymph node metastasis ( P = 0.04), and liver metastasis ( P < 0.001). There was a weakly positive correlation between the serum carcinoembryonic antigen (CEA) level and the serum TIMP-1 level. In patients who underwent potentially curative resection, the disease-free survival was not different between those with a high TIMP-1 level (>=203.5 ng/ml, n = 32) and those with a low TIMP-1 level (<203.5 ng/ml, n = 66, P = 0.62). In patients with Dukes' stage D cancer who underwent noncurative resection, the survival times were not different between those with a high TIMP-1 level ( n = 13) and those with a low TIMP-1 level ( n = 10, P = 0.20).
CONCLUSIONS: Elevated levels of serum TIMP-1 reflect the extent of colorectal cancer, without a close correlation with the serum CEA level. These findings suggest that measuring the serum TIMP-1 level would not help to predict the prognosis of patients with colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14669077     DOI: 10.1007/s00595-003-2628-x

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  10 in total

1.  Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers.

Authors:  Hong In Yoon; Woong Sub Koom; Yong Bae Kim; Byung Soh Min; Kang Young Lee; Nam Kyu Kim; Sang Joon Shin; Joong Bae Ahn; Ki Chang Keum
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-04       Impact factor: 4.553

2.  Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil recruitment in mice.

Authors:  Bastian Seubert; Barbara Grünwald; Julia Kobuch; Haissi Cui; Florian Schelter; Susanne Schaten; Jens T Siveke; Ngee H Lim; Hideaki Nagase; Nicole Simonavicius; Mathias Heikenwalder; Thomas Reinheckel; Jonathan P Sleeman; Klaus-Peter Janssen; Percy A Knolle; Achim Krüger
Journal:  Hepatology       Date:  2014-11-24       Impact factor: 17.425

3.  The matrix metalloproteinase-7 and pro-enzyme of metalloproteinase-1 as a potential marker for patients with rectal cancer without distant metastasis.

Authors:  Malgorzata Fuksiewicz; Beata Kotowicz; Andrzej Rutkowski; Maria Kowalska
Journal:  Tumour Biol       Date:  2014-12-31

4.  The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients.

Authors:  Barbara Mroczko; Magdalena Groblewska; Bogna Okulczyk; Bogusław Kedra; Maciej Szmitkowski
Journal:  Int J Colorectal Dis       Date:  2010-06-17       Impact factor: 2.571

Review 5.  Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled.

Authors:  Kim Y C Fung; Edouard Nice; Ilka Priebe; Damien Belobrajdic; Aloke Phatak; Leanne Purins; Bruce Tabor; Celine Pompeia; Trevor Lockett; Timothy E Adams; Antony Burgess; Leah Cosgrove
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

6.  Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer.

Authors:  Takaki Yoshikawa; Haruhiko Cho; Akira Tsuburaya; Osamu Kobayashi
Journal:  Gastric Cancer       Date:  2009-04-24       Impact factor: 7.370

7.  TIMP1 intron 3 retention is a marker of colon cancer progression controlled by hnRNPA1.

Authors:  Marion Flodrops; Gwendal Dujardin; Adeline Busson; Pascal Trouvé; Chandran Ka; Brigitte Simon; Danielle Arzur; Catherine Le Jossic-Corcos; Laurent Corcos
Journal:  Mol Biol Rep       Date:  2020-03-21       Impact factor: 2.316

8.  Differences in plasma TIMP-1 levels between healthy people and patients with rectal cancer stage II or III.

Authors:  Irena Oblak; Franc Anderluh; Vaneja Velenik; Barbara Mozina; Janja Ocvirk; Eva Ciric; Natasa Hrovatic Podvrsnik
Journal:  Radiol Oncol       Date:  2011-08-26       Impact factor: 2.991

9.  The correlation between the levels of tissue inhibitor of metalloproteinases 1 in plasma and tumour response and survival after preoperative radiochemotherapy in patients with rectal cancer.

Authors:  Irena Oblak; Vaneja Velenik; Franc Anderluh; Barbara Mozina; Janja Ocvirk
Journal:  Radiol Oncol       Date:  2013-05-21       Impact factor: 2.991

Review 10.  Confounding factors of non-invasive tests for nonalcoholic fatty liver disease.

Authors:  Janae Wentong Wai; Charmaine Fu; Vincent Wai-Sun Wong
Journal:  J Gastroenterol       Date:  2020-05-25       Impact factor: 7.527

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.